期刊文献+

转染血小板因子4基因或其片段在动物体内抑制多发性骨髓瘤的生长

Suppression of Multiple Myeloma Tumor Growth In Vivo by Transfection of Platelet Factor 4 or 17-70 cDNA
下载PDF
导出
摘要 本研究旨在观察血小板因子4cDNA全长或其17-70片段转染多发性骨髓瘤细胞株对其在动物体内生长的影响。构建含有人血小板因子4cDNA全长或17-70片段的慢病毒载体,转染、筛选并检测稳定表达转染基因蛋白的多发性骨髓瘤U266细胞株。用稳定表达转染基因蛋白的U266细胞建立多发性骨髓瘤联合免疫缺陷小鼠动物模型。每2周检测小鼠血清中人轻链蛋白的含量,每4周测量小鼠血清中人VEGF及PF4蛋白含量。并检测肿瘤的体积和肿瘤内血管密度以及小鼠的生存期。结果表明:成功筛选出稳定表达血小板因子4蛋白和其17-70肽段的多发性骨髓瘤细胞株。筛选后各组多发性骨髓瘤细胞上清液内VEGF含量之间有统计学差异(p<0.01)。应用转染后多发性骨髓瘤细胞建立小鼠多发性骨髓瘤模型发现,和转染空载体组相比较,转染血小板因子4基因组小鼠血清中人VEGF及人轻链蛋白含量降低,在转染17-70片段组的降低更加明显(p<0.05)。各组小鼠肿瘤平均体积及肿瘤组织内微血管密度之间有统计学差异(p<0.05)。转染空载体组小鼠与其它两组小鼠之间生存期有统计学差异(p<0.05)。转染血小板因子4小鼠与转染血小板因子4片段组小鼠之间生存期无统计学差异(p>0.05)。结论:转染血小板因子4cDNA全长或其17-70片段的多发性骨髓瘤细胞在小鼠体内生长受到抑制,小鼠生存期延长。 This study was purposed to investigate the effects of viral vector-mediated gene transfer of platelet factor 4(PF4) or 17-70 cDNA on cell growth of multiple myeloma(MM) in vivo.Full length and p17-70 cDNA of PF4 were cloned into virapowerTM system to transfect packing cell line 293 and produce lentiviral vectors.3 multiple myeloma cell lines were transferred platelet factor 4 or 17-70 cDNA by lentiviral vectors.SCID-rab mice models of multiple myeloma were established by injecting U266 multiple myeloma cells selected.The human light chain proteins and VEGF in serums of mice were detected every 2 weeks.The volumes and vascular density of tumors as well as survival time of mice were observed.The results showed that the MM cells expressing foreign genes were identified and screened.There were significant difference of VEGF levels in the supernatants of MM cells between each groups(p0.01).The SCID-rab models of U266 cells were established successfully.There were significant differences in light chain protein and VEGF in serums among three groups(p0.01).The light chain protein and VEGF in mice serums of 17-70 cDNA groups were less than that of PF4 group(p0.01).The light chain protein and VEGF in mice serums of PF4 group were less than that of control group(p0.01).There were significant differences in the tumor volumes and the vascular density of tumor among 3 groups(p0.05).The results also showed that there were significant differences of overall survival in 3 different groups of SCID-rab MM models.The overall survival in control group was shortest as compared with other groups(p0.05).It is concluded that the cell growth of multiple myeloma is suppressed in vivo by transfection of platelet factor 4 or 17-70 cDNA and the overall survivl of transfected mice will be prolonged.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第5期1172-1176,共5页 Journal of Experimental Hematology
基金 国家自然科学基金资助项目 编号30731160619
关键词 血小板因子4 多发性骨髓瘤 抗血管新生 基因治疗 platelet factor 4 multiple myeloma antiangiogenesis gene therapy
  • 相关文献

参考文献10

  • 1Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCIA and CXLA L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood, 2007; 109(10) :4127 - 4134.
  • 2Yamaguchi K, Ogawa K, Katsube T, et al. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res, 2005 ; 25 (2A) :847 - 851.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009, CA Cancer J Clin, 2009 ; 59 (4) :225 - 249.
  • 4Appelmann I, Liersch R, Kessler T, et al. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. Recent Results Cancer Res, 2010; 180:51 -81.
  • 5Lu Y, Madu CO. Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert Opin Drug Deliv, 2010; 7(1) :19 -35.
  • 6Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138- expressing malignant cells. Leukemia, 2004; 18 ( 11 ), 1891 - 1897.
  • 7黄豪博,战榕.VEGF反义RNA促骨髓瘤细胞凋亡及抑制内皮细胞形成血管作用的体外研究[J].中国实验血液学杂志,2008,16(2):312-316. 被引量:4
  • 8Vandercappellen J, Liekens S, Bronckaers A, et al. The COOH- terminal peptide of platelet factor-4 variant ( CXCL4L1/PF-4var47 -70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol Cancer Res, 2010; 8(3):322 -334.
  • 9张曦,司英健,陈幸华,刘耀,高力,高蕾,彭贤贵,王庆余.Ad-vcam-1-gfp重组腺病毒转染人脐血源基质细胞的实验研究[J].中国实验血液学杂志,2008,16(3):598-604. 被引量:1
  • 10窦立萍,达万明,王畅,康慧媛,赵瑜,孙敬芬,靳海杰,王全顺,高春记,于力.Kir2ds4基因RNAi慢病毒载体的构建与鉴定[J].中国实验血液学杂志,2008,16(3):663-666. 被引量:5

二级参考文献28

  • 1张曦,王苹,陈幸华,刘林,彭贤贵,孔佩艳,刘红,张怡,王庆余.人脐血贴壁细胞生物学特点的观察[J].中国实验血液学杂志,2005,13(1):59-64. 被引量:5
  • 2潘立峰,李巧霞,单保恩,王俊霞.VEGF反义RNA对人食管癌细胞抑制作用的研究[J].中国肿瘤生物治疗杂志,2005,12(1):41-45. 被引量:5
  • 3高蕾,陈幸华,张曦,彭贤贵,孔佩艳,刘林,刘红,张怡,刘耀.VCAM-1基因的克隆及VCAM-1-pcDNA3.1(+)真核表达载体的构建[J].重庆医学,2005,34(9):1310-1312. 被引量:2
  • 4崔国惠,陈卫华,薛克营,刘芳,陈燕.肿瘤坏死因子α和雷公藤内酯醇调节Raji细胞内VEGF的表达及基质胶中ECV304细胞血管形成作用的研究(英文)[J].中国实验血液学杂志,2006,14(5):1008-1012. 被引量:11
  • 5Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 2005; 105: 1383 - 1395
  • 6Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res, 2002; 8:2210-2216
  • 7Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res, 2000; 6:3111 -3116
  • 8Ellis LM, Staley CA, Liu W, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem, 1998 ;273 : 1052 - 1057
  • 9Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res, 1996;56:393 -401
  • 10He R, Liu B, Yang C, et al. Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Gene Ther, 2003;10:879 -886

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部